Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 56.7× earnings vs its 27.3× historical median P/E.
Fair value ≈ $5.30 · price $11.00 today
Overvalued · 108% above
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Eyes on $NFYS — coming out the gate with momentum.
But check this company — expanding from colorectal to pancreatic cancer with ColoAlert® showing 97% sensitivity. Strong trials, key partnerships, and FDA plans point to major U.S. growth in early cancer detection.
$NFYS Enphys Acquisition Corp. (NFYS): A Blank Check Company Poised for Transformative Growth https://beyondspx.com/article/enphys-acquisition-corp-nfys-a-blank-check-company-poised-for-transformative-growth
From 7/14/2023, looking back across 21 Month-Ends for NFYS, Percentage Change of Average Monthly Price had More Positives (80%) while Percentage Change of Average Monthly Volume had All Positives (100%) $NFYS #NFYS #NFYSStock #TickerDD #NFYSPrice https://www.youtube.com/watch?v=-2146826273
$NFYS: The long and short term trends are both positive. This is looking good! https://www.chartmill.com/stock/quote/NFYS/technical-analysis?key=a874ccec-4ba2-47d3-a6bf-7812ca1e34ac&utm_source=stocktwits&utm_medium=TA&utm_content=NFYS&utm_campaign=social_tracking
From 3/23/2023, looking back across 17 Month-Ends for NFYS, Percentage Change of Average Monthly Price had More Positives (75%) while Percentage Change of Average Monthly Volume had All Positives (100%) $NFYS #NFYS #NFYSStock #TickerDD #NFYSPrice https://www.youtube.com/watch?v=IXiiAb50N_E
